Editas Medicine, Inc.

Editas Medicine is a clinical stage genome editing company that develops transformative genomic medicines using its proprietary CRISPR-based gene editing platform. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol by upregulating the LDL receptor to treat hyperlipidemia. The company is also developing therapies for sickle cell disease and transfusion-dependent beta thalassemia, as well as in vivo gene editing medicines for other cells and tissues. Additionally, Editas has a research collaboration with Juno Therapeutics to develop alpha-beta T-cell experimental medicines for solid and liquid tumors and autoimmune diseases.

Editas Medicine is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol EDIT. Its shares are traded in US Dollars (USD), reflecting its primary listing in the United States.

Editas Medicine operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical stage genome editing company, it focuses on developing genomic medicines based on CRISPR technology to treat serious diseases, including genetic blood disorders and hyperlipidemia.

Editas Medicine is headquartered in Cambridge, Massachusetts, United States. The company was originally founded as Gengine, Inc. and rebranded to Editas Medicine in November 2013. It was incorporated in 2013 and has since become a clinical stage biotechnology company focused on CRISPR-based gene editing therapies.